Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...

Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...